Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: Several evidence-based practice guidelines have been developed to better treat bipolar disorder. However, the articles cited in these guidelines were based on clinical or basic studies with specific conditional settings and were not sufficiently based on real-world clinical practice. In particular, there was little information on the doses of mood stabilizers. Methods: The MUlticenter treatment SUrvey on BIpolar disorder in Japanese psychiatric clinics (MUSUBI) is a study conducted to accumulate evidence on the real-world practical treatment of bipolar disorder. The questionnaire included patient characteristics such as comorbidities, mental status, treatment period, Global Assessment of Functioning (GAF) score, and details of pharmacological treatment. Results: Most patients received mood stabilizers such as lithium (n = 1,317), valproic acid (n = 808), carbamazepine (n = 136), and lamotrigine (n = 665). The dose of lithium was correlated with age, body weight, number of episodes, depression and GAF. The dose of valproic acid was correlated with body weight, number of episodes, presence of a rapid cycle and GAF. The dose of carbamazepine was correlated with age, mania, and the presence of a rapid cycle. The dose of lamotrigine was correlated with the number of episodes, depression, mania, psychotic features, and the presence of a rapid cycle. Doses of coadministered mood stabilizers were significantly correlated, except for the combination of valproic acid and lamotrigine. Conclusion: The dose of mood stabilizers was selectively administered based on several factors, such as age, body composition, current mood status and functioning. Further prospective studies are required to confirm these findings.
Abstract
Objective: Several evidence-based practice guidelines have been developed to better treat bipolar disorder. However, the articles cited in these guidelines were based on clinical or basic studies with specific conditional settings and were not sufficiently based on real-world clinical practice. In particular, there was little information on the doses of mood stabilizers. Methods: The MUlticenter treatment SUrvey on BIpolar disorder in Japanese psychiatric clinics (MUSUBI) is a study conducted to accumulate evidence on the real-world practical treatment of bipolar disorder. The questionnaire included patient characteristics such as comorbidities, mental status, treatment period, Global Assessment of Functioning (GAF) score, and details of pharmacological treatment. Results: Most patients received mood stabilizers such as lithium (n = 1,317), valproic acid (n = 808), carbamazepine (n = 136), and lamotrigine (n = 665). The dose of lithium was correlated with age, body weight, number of episodes, depression and GAF. The dose of valproic acid was correlated with body weight, number of episodes, presence of a rapid cycle and GAF. The dose of carbamazepine was correlated with age, mania, and the presence of a rapid cycle. The dose of lamotrigine was correlated with the number of episodes, depression, mania, psychotic features, and the presence of a rapid cycle. Doses of coadministered mood stabilizers were significantly correlated, except for the combination of valproic acid and lamotrigine. Conclusion: The dose of mood stabilizers was selectively administered based on several factors, such as age, body composition, current mood status and functioning. Further prospective studies are required to confirm these findings.
참고문헌 (27)
- Parker GB, "Is there consensus across international evidence-based guidelines for the management of bipolar disorder?", Acta Psychiatr Scand, 135, pp.515~526 (2017)
- Miura T, "Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder : a systematic review and network metaanalysis", Lancet Psychiatry, 1, pp.351~359 (2014)
- Fountoulakis KN, "The International College of Neuro-Psychopharmacology(CINP)treatment guidelines for bipolar disorder in adults(CINP-BD-2017), part 3 : the clinical guidelines", Int J Neuropsychopharmacol, 20, pp.180~195 (2017)
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
- Hiemke C, "Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology : update 2017", Pharmacopsychiatry, 51, pp.e1~ (2018)
- Steen NE, "Serum concentrations of mood stabilizers are associated with memory, but not other cognitive domains in psychosis spectrum disorders; explorative analyses in a naturalistic setting", Int J Bipolar Disord, 4, pp.24~ (2016)
- "Regarding compliance with blood concentration measurement during administration of lithium carbonate; request of the pharmaceutical products proper use from Pharmaceuticals and Medical Devices Agency (PMDA)" (2012)[URL]
- Murru A, "Management of adverse effects of mood stabilizers", Curr Psychiatry Rep, 17, pp.603~ (2015)
- Adachi N, "Estimated population with affective disorders in membership clinics of the Japanese Association of Neuro-Psychiatric Clinics", J Jpn Assoc Psychiatr Clin, 42, pp.957~959 (2016)
- Tsuboi T, "Factors associated with non-remission in bipolar disorder : the multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics(MUSUBI)", Neuropsychiatr Dis Treat, 16, pp.881~890 (2020)
- Wang PW, "Pharmacokinetics of mood stabilizers and new anticonvulsants", Psychopharmacol Bull, 36, pp.44~66 (2002)
- Williams L, "Drug therapy in the elderly", South Med J, 85, pp.127~131 (1992)
- Greenblatt DJ, "Sensitivity to triazolam in the elderly", N Engl J Med, 324, pp.1691~1698 (1991)
- Fountoulakis KN, "A systematic review of the evidence on the treatment of rapid cycling bipolar disorder", Bipolar Disord, 15, pp.115~137 (2013)
- Calabrese JR, "A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder", J Clin Psychiatry, 61, pp.841~850 (2000)
- Baldessarini RJ, "Does lithium treatment still work? Evidence of stable responses over three decades", Arch Gen Psychiatry, 57, pp.187~190 (2000)
- Soares JC, "The psychopharmacologic specificity of the lithium ion: origins and trajectory", J Clin Psychiatry, 61(Suppl 9), pp.16~22 (2000)
- Grof P, "The challenge of predicting response to stabilising lithium treatment. The importance of patient selection", Br J Psychiatry Suppl, (21), pp.16~19 (1993)
- Calabrese JR, "Predictors of response to mood stabilizers", J Clin Psychopharmacol, 16(2 Suppl 1), pp.24S~31S (1996)
- Bowden CL, "Clinical correlates of therapeutic response in bipolar disorder", J Affect Disord, 67, pp.257~265 (2001)
- Kleindienst N, "Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders", Bipolar Disord, 7, pp.404~417 (2005)
- Ketter TA, "Predictors of treatment response in bipolar disorders : evidence from clinical and brain imaging studies", J Clin Psychiatry, 63(Suppl 3), pp.21~25 (2002)
- Alda M, "The phenotypic spectra of bipolar disorder", Eur Neuropsychopharmacol, 14(Suppl 2), pp.S94~S99 (2004)
- De León OA, "Antiepileptic drugs for the acute and maintenance treatment of bipolar disorder", Harv Rev Psychiatry, 9, pp.209~222 (2001)
- Obrocea GV, "Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders", Biol Psychiatry, 51, pp.253~260 (2002)
- Passmore MJ, "Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine", Bipolar Disord, 5, pp.110~114 (2003)